Pharmacyclics Llc patents expiration
1. Imbruvica patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 24, 2029 |
| New Patient Population (NPP) | Aug 24, 2025 |
| ODE* (ODE*) | May 6, 2023 |
| Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 13 November, 2013
Treatment: Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia with 17p deleti...
Dosage: CAPSULE;ORAL
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic